gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HCWBHealthcarePharmaceuticals

HCW Biologics Inc. Common Stock (HCWB)

$1.08−6.09%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.08▼ 94.71% in range
Nov 4, 2025Low $1.08 · High $31.54Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

HCW Biologics closed at $1.08 on Nov 4, down 6.09%, within 0.0% of its 52-week closing low. Volume of 18.3K shares was 0.11× its 20-day average (below normal).

Split-adjusted performance: -31.2% over one month, -48.6% over six months, -95.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $135.57K, up 1969.7% from a year earlier, with a net margin of -11340.3%.

Short interest was 37.7K shares at the Oct 15 settlement, down 38.1% from the prior report (2.3% of float, 1.0 days to cover).

Market cap$2.4M2.2M shares
Revenue · quarter$135.6K+1969.7% YoY
Diluted EPS$-11.58—
P/E · TTM—P/S 0.4×
Net margin-11,340.3%Gross -69.3%
Dividend yieldNone
52-week range1.08 – 31.54−96.6% from high
Volume18.3K0.11× 20-day avg
Volatility · 60d108.7%Annualised
Short % of float2.3%1.0 days to cover
Net cash-$5.8MCash $741.3K
Next earnings—Not scheduled
Split-adjusted performance
1W −11.5%1M −31.2%3M −68.3%6M −48.6%YTD −81.5%1Y −95.0%3Y −99.7%5Y −99.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum27
Revenue growth97
Net margin5
Value (low P/E)—
Size4

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short37.7K−38.1% vs prior
Days to cover1.0Settled Oct 15
% of float2.3%
Short vol. 10d38.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HCWBHCW Biologics$1.08−6.09%−48.6%+1969.7%−11340.3%—$2.4M
APVOAptevo Therapeutics$1.37+0.74%−72.3%———$2.5MCompare
REVBRevelation Biosciences$4.12−7.05%−42.3%———$2.3MCompare
ERNAErnexa Therapeutics$1.99−1.49%−67.1%———$2.3MCompare
SILOSilo Pharma$1.33+3.91%−78.9%−100.0%——$2.9MCompare
SBFMSunshine Biopharma$2.65−3.28%−98.8%−1.6%−16.9%—$2.0MCompare
GRIGRI Bio$1.43−7.14%−39.4%———$3.1MCompare
MBIOMustang Bio$0.4138+1.07%−44.6%———$3.1MCompare
JUNSJupiter Neurosciences$2.46+1.23%−91.0%—−9380.9%—$3.2MCompare

News about HCW Biologics

All news →
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T CellsGlobeNewswire Inc. · Sep 8, 2026▲ PositiveHCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026GlobeNewswire Inc. · Jun 26, 2026Neutral

Quick answers

What does HCW Biologics do?
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia.
What is HCWB's market cap?
$2.42M, based on the Nov 4 close of $1.08.
Does HCW Biologics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HCWB is sold short?
37.7K shares, 2.3% of float, as of Oct 15, 2026.
What sector is HCWB in?
Healthcare, in the Pharmaceuticals industry.

About HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

HQ: Miramar, FL35 employeesListed Jul 20, 2021hcwbiologics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology